All In Biotech

Free tool

FAERS Monitor: Kadcyla

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125427 or its brand name (Kadcyla, Ado-Trastuzumab Emtansine). Reports on generic versions are filed under their own applications.

Reports

8,459

Serious

6,979

83% of reports

Hospitalization

2,172

Death reported

1,171

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • disease progression807
  • fatigue759
  • nausea741
  • off label use647
  • diarrhoea605
  • death565
  • thrombocytopenia485
  • neuropathy peripheral457
  • platelet count decreased438
  • headache436
  • metastases to central nervous system409
  • drug ineffective406
  • vomiting352
  • pyrexia338
  • epistaxis322

Reports by year received

View as table
YearReports
201211
2013157
2014296
2015671
2016371
2017377
2018456
2019455
2020619
2021889
20221,039
20231,091
20241,085
2025635
2026307

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,700 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
metastases to central nervous systemSignal40981.473.931,389
disease progressionSignal80717.116.012,176
neuropathy peripheralSignal45712.011.04,595
thrombocytopeniaSignal48510.89.94,320
epistaxisSignal32210.79.72,834
platelet count decreasedSignal43810.39.43,653
pyrexiaSignal3382.42.2288
fatigueSignal7592.42.3658
diarrhoeaSignal6052.32.2473
nauseaSignal7412.32.2582
vomiting3521.91.7143
off label use6471.81.7257
headache4361.71.6137
death5651.61.5143
drug ineffective4060.80.731

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.